Samsung Biologics Co., Ltd.

Samsung Biologics is an end-to-end CDMO partner of choice, providing highly tailored solutions to clients while meeting the evolving needs of the global healthcare industry. With proven regulatory approvals, the company provides seamless offerings from cell-line development to final fill/finish at every stage for biopharmaceutical products, operating cGMP-compliant plants with a wide range of bioreactor scales; upon full completion of Plant 4 in the first half of 2023, Samsung Biologics holds total capacity of 604 kL at Bio Campus I, the world's largest biomanufacturing site, accounting for one-fourth of global CDMO manufacturing capacity.